News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)Why we need to avoid recurrent events: Plaque biology considerations REDUCE-IT- does the formulation matter?REDUCE-IT take home messages ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

Latest News Updates

Events

Posted on 14 November 2016 |

European Society of Cardiology Congress
Event start date: 25 Aug 2018
Munich, Germany

14th Asian Interventional Cardiovascular Therapeutics Congress 2018 (AICT 2018)
Event start date: 7 Sep 2018
Wan Chai, Hong Kong

73rd Brazilian Congress Of Cardiology 2018 (SBC 2018)
Event start date: 14 Sep 2018
Brasília, Brazil

NLA Clinical Lipid Update
Event start date: 21 Sep 2018
Nashville, USA

23rd ASEAN Federation of Cardiology Congress 2018 (AFCC 2018)
Event start date: 28 Sep 2018
Bangkok Thailand

British Association For Cardiovascular Prevention And Rehabilitation Annual Conference 2018 (BACPR 2018)
Event start date: 4 Oct 2018
Glasgow, UK

Cardiometabolic Health Congress 2018 (CMHC 2018)
Event start date: 24 Oct 2018
Boston, USA

American Heart Association Scientific Sessions 2018 (AHA 2018)
Event start date: 10 Nov 2018
Chicago, USA

World Heart Federation World Congress of Cardiology & Cardiovascular Health 2018 (WHF 2018)
Event start date: 5 Dec 2018
Dubai, UAE

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. The PCSK9 Education and Research Forum is focused on raising awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target. As part of its remit, PCSK9 Education and Research Forum offers healthcare professionals open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; as well as an extensive library of accredited educational materials tailored to the differing needs of registrants.

Our Partnership and Outreach

Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum connects academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum builds on educational partnerships with such organisations through jointly sponsored symposia, as well as accredited research and educational programmes.

Educational Partners and Supporters

Amgen

The Medicines Company

Sanofi Regeneron

Amgen

The Medicines Company

Sanofi Regeneron

Amgen

The Medicines Company

Sanofi Regeneron

The Medicines Company

Sanofi Regeneron

© Copyright 2018 PCSK9 Forum. All rights reserved